

DAFTAR PUSTAKA

- Barnieh, L., Clement, F., Harris, A., Blom, M., Donaldson, C., Klarenbach, S., dkk., 2014. A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development. *PLoS ONE* 9: e90434.
- Ben-Aharon, O., Sergienko, R., Iskrov, G., dan Greenberg, D., 2024. Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel. *Israel Journal of Health Policy Research* 13: 9.
- Boyle, K.J., Bishop, R.C., dan Welsh, M.P., 1984. 'Starting Point Bias in Contingent Valuation Bidding Games,' 1984 Annual Meeting Papers. United States.
- BPJS Kesehatan, 2026. 'Dashboard Cakupan Kepesertaan Program JKN per 28 Februari 2026' *Portal Data BPJS Kesehatan*.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., dkk., 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 74: 229–263.
- Cameron, D., Piccart-Gebhart, M.J., Gelber, R.D., Procter, M., Goldhirsch, A., de Azambuja, E., dkk., 2017. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *The Lancet* 389: 1195–1205.
- Carson, R.T. dan Hanemann, W.M., 2005. Chapter 17 Contingent Valuation. hal. 821–936.
- Dewan Jaminan Sosial Nasional, 2025. 'Monthly Report Monitoring JKN (31 Oktober 2025).'
- Drummond, M.E., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., dan Stoddart, G.L., 2005. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press Oxford.
- Dzulkipli, M.R., Shafie, A.A., Maon, S.N., Ramli, A., Mohammad Yahaya, A.H., Ho, S.W., dkk., 2025. ASSESSING THE DISTRIBUTION OF SELF-PAYING INNOVATIVE ONCOLOGY MEDICINES AMONG CANCER PATIENTS. *Jurnal Administrasi Kesehatan Indonesia* 13: 162–171.
- Dzulkipli, M.R., Shafie, A.A., Maon, S.N., Ramli, A., Yahaya, A.H.M., Ho, S.W., dkk., 2024. Determining the Willingness to Pay for Innovative Oncology Medicines in Malaysia. *Value in Health Regional Issues* 40: 19–26.
- Eka Darmawati dan Anom Dwi Prakoso, 2023. ABILITY TO PAY DAN WILLINGNESS TO PAY PESERTA MANDIRI TERHADAP PENENTUAN KELAS IURAN JKN DI KABUPATEN BEKASI. *Cakrawala Medika: Journal of Health Sciences* 1: 56–64.
- Ettinger, D.S., Aisner, D.L., Wood, D.E., Akerley, W., Bauman, J., Chang, J.Y., dkk., 2018. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. *Journal of the National Comprehensive Cancer Network* 16: 807–821.
- Feldstein, P.J., 2011. *Health Care Economics*, 7 ed. Delmar Cengage Learning, Clifton Park, NY.

- Frey, U.J. dan Pirscher, F., 2019. Distinguishing protest responses in contingent valuation: A conceptualization of motivations and attitudes behind them. *PLOS ONE* 14: e0209872.
- Giddings, F.H., 1890. *PRINCIPLES OF ECONOMICS*. By Alfred Marshall, Professor of Political Economy in the University of Cambridge. MacMillan & Co., London and New York, 1890. Vol. I, pp. xxviii, 754. *The ANNALS of the American Academy of Political and Social Science* 1: 332–337.
- Han, K.-T., Yu, Y.L., Kim, W., dan Kang, S., 2021. Is Korean society prepared for the financial burden of novel anticancer drugs? A survey of willingness to pay among National Health Insurance beneficiaries. *Supportive Care in Cancer* 29: 6681–6688.
- Hidayat, M.S., Permana, Y.H., Puspendari, D.A., Siregar, D.R., Setyaningsih, H., Aristianti, V., dkk., 2025. Payment compliance of informal sector workers in Indonesia National Health Insurance: a study on ability and willingness to pay. *Health Economics Review* 15: 109.
- Huang, L., Peng, X., Sun, L., dan Zhang, D., 2023. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China. *Cost Effectiveness and Resource Allocation* 21: 37.
- IPMG, 2024. 'IPMG manifesto for a national strategy for new medicines & vaccines in Indonesia.' Jakarta.
- Iqbal, M., Yeni, R., Kusumastuti, I., Studi Sarjana Kesehatan Masyarakat, P., dan Ilmu Kesehatan, F., 2023. Faktor-Faktor yang Mempengaruhi Kemauan Membayar (Willingness To Pay) Iuran Program Jaminan Kesehatan Nasional Pada Pekerja Sektor Informal Di Kota Jakarta Timur Tahun 2023 Factors Influencing Willingness to Pay National Health Insurance Program Contributions for Informal Sector Workers in East Jakarta City in 2023.
- Kementerian Kesehatan Republik Indonesia, 2018. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 22 Tahun 2018 tentang Petunjuk Teknis Restriksi Penggunaan Obat Trastuzumab untuk Kanker Payudara Metastatik pada Pelayanan Jaminan Kesehatan Nasional*, Kementerian Kesehatan Republik Indonesia. Kementerian Kesehatan Republik Indonesia, Indonesia.
- Kementerian Kesehatan RI, 2024. 'Rencana Kanker Nasional 2024–2034: Strategi Indonesia dalam Upaya Melawan Kanker.' Jakarta.
- Khoiri, A., Sandra, C., Putra, D.N.G.W.M., dan Herawati, Y.T., 2025. Analisis Willingness to Pay (WTP) Peserta BPJS Kesehatan Dengan Pendekatan Contingent Valuation Method. *ARTERI: Jurnal Ilmu Kesehatan* 6: 71–77.
- Khoirunnisa, S.M., Suryanegara, F.D.A., Setiawan, D., Postma, M.J., dan de Jong, L.A., 2024. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. *PLOS ONE* 19: e0304483.
- Kioe, S., 2025. 'Analisis Kesiediaan Membayar Iuran Jaminan Kesehatan Nasional dengan Skema Cost-Sharing dan Faktor-Faktor yang Memengaruhinya: Studi pada Masyarakat di Wilayah Jabodetabek.' *Skripsi*. Universitas Gadjah Mada, Yogyakarta.
- Kristin, E., Endarti, D., Khoe, L., Taroeno-Hariadi, K., Trijayanti, C., Armansyah, A., dkk., 2021. Economic Evaluation of Adding Bevacizumab to

- Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. *Asian Pacific Journal of Cancer Prevention* 22: 1921–1926.
- Lemeshow, S., Ogston, S.A., Hosmer, D.W., Klar, J., dan Lwanga, S.K., 1991. Adequacy of Sample Size in Health Studies. *Biometrics* 47: 347.
- Newhouse, J.P., Manning, W.G., Morris, C.N., dan Orr, L.L., 1987. ‘Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment.’ Santa Monica, CA .
- Nugraheni, D.A., Satibi, S., Kristina, S.A., dan Puspandari, D.A., 2022. Factors Associated with Willingness to Pay for Cost-Sharing under Universal Health Coverage Scheme in Yogyakarta, Indonesia: A Cross-Sectional Survey. *International Journal of Environmental Research and Public Health* 19: 15017.
- Nugraheni, D.A., Satibi, S., Kristina, S.A., dan Puspandari, D.A., 2023. Development of Questionnaire on Willingness-to-Pay for Health Insurance Cost-Sharing for Catastrophic Prescription Drugs. *Indonesian Journal of Pharmacy*.
- OECD, 2019. ‘Self-rated health and disability at age 65 and over (Health at a Glance 2019: OECD Indicators)’ *OECD Publishing*.
- Prasetya, D., Layyindah, A., Maftuchan, Ah., Putri, S., Rosita, E., dan Nurjanah, A.I., 2023. ‘Konsekuensi Finansial Pengobatan Kanker di Indonesia: Studi Kasus Penderita Kanker di Ibu Kota Jakarta.’ Indonesia.
- Pratikto, F.R., 2021. Preference-Based Pricing of the Indonesian JKN-KIS Health Insurance for Urban Middle-Income Self-Funders. *Jurnal Kesehatan Masyarakat* 17: 75–84.
- Presiden Republik Indonesia, 2024. *Peraturan Presiden Nomor 59 Tahun 2024 tentang Perubahan Ketiga atas Peraturan Presiden Nomor 82 Tahun 2018 tentang Jaminan Kesehatan*, Sekretariat Negara. Indonesia.
- Putra, A.P., Inayah, M., Albana, S.S., Permata, M., Nuryadi, E., dan Gondhowiardjo, S., 2024. P76-2 Financial catastrophe in cancer patients having radiotherapy under Indonesia’s health insurance scheme: midterm results. *Annals of Oncology* 35: S1388–S1389.
- Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., dkk., 2020. Overall Survival with Osimertinib in Untreated, *EGFR* -Mutated Advanced NSCLC. *New England Journal of Medicine* 382: 41–50.
- Republik Indonesia, 2004. *Undang-Undang Nomor 40 Tahun 2004 tentang Sistem Jaminan Sosial Nasional*, Sekretariat Negara. Indonesia.
- Republik Indonesia, 2023. *Undang-Undang Nomor 17 Tahun 2023 tentang Kesehatan*, Sekretariat Negara. Indonesia.
- Rezaei, M.A., Poursaghari, H., Karimi, F., Rajaie, S., Shahmohammady, A., Behzadifar, M., dkk., 2025. Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review. *European Journal of Clinical Pharmacology* 81: 1733–1743.
- Rianya, R., Louisa, M., Syahrudin, E., dan Soetikno, V., 2022. Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia. *eJournal Kedokteran Indonesia* 9: 178–86.

- Ryman, C., Warnicke, C., Hugosson, S., Zakrisson, A.-B., dan Dahlberg, K., 2024. Health literacy in cancer care: A systematic review. *European Journal of Oncology Nursing* 70: 102582.
- Salasifah, E., Putri, D.F., dan Fajriyani, F.K., 2026. Determinants of Public Health Behavior Based on the Health Belief Model: A Systematic Review. *Jurnal Promosi Kesehatan Indonesia* 21: 180–194.
- Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., dkk., 2006. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. *New England Journal of Medicine* 355: 2542–2550.
- Sastroasmoro, S. dan Ismael, S., 2018. *Dasar-Dasar Metodologi Penelitian Klinis*, 5 ed. Sagung Seto, Jakarta.
- Sendi, P., Ramadani, A., dan Bornstein, M.M., 2021. Prevalence of Missing Values and Protest Zeros in Contingent Valuation in Dental Medicine. *International Journal of Environmental Research and Public Health* 18: 7219.
- Steigenberger, C., Flatscher-Thoeni, M., Siebert, U., dan Leiter, A.M., 2022. Determinants of willingness to pay for health services: a systematic review of contingent valuation studies. *The European Journal of Health Economics* 23: 1455–1482.
- Sulianto, E.K., 2025. ‘Analisis Kesiediaan Membayar Iuran Jaminan Kesehatan Nasional dengan Skema Cost-Sharing dan Faktor-Faktor yang Memengaruhinya: Studi pada Masyarakat di Wilayah Daerah Istimewa Yogyakarta.’ *Skripsi*. Universitas Gadjah Mada, Yogyakarta.
- Thongprasert, S., Crawford, B., Sakulbumrungsil, R., Chaiyakunapruk, N., Petcharapiruch, S., Leartsakulpanitch, J., dkk., 2015. WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES. *International Journal of Technology Assessment in Health Care* 31: 264–270.
- Varian, H.R., 1992. *Microeconomic analysis*. Norton.
- World Health Organization dan International Bank for Reconstruction and Development, 2023. ‘Tracking Universal Health Coverage: 2023 Global Monitoring Report.’ Geneva.
- Yong, A.S.J., Lim, Y.H., Cheong, M.W.L., Hamzah, E., dan Teoh, S.L., 2022. Willingness-to-pay for cancer treatment and outcome: a systematic review. *The European Journal of Health Economics* 23: 1037–1057.
- Yuliasuti, F., Andayani, T.M., Endarti, D., dan Kristina, S.A., 2024. Cost determinant of chemotherapy in breast, cervical, and lung cancer in the era of National Health Insurance. *Pharmacy Practice* 22: 1–10.
- Zhang, Q., Ren, D., Chang, X., Sun, C., Liu, R., Wang, J., dkk., 2023. Willingness to pay for packaging cancer screening of Chinese rural residents. *Cancer Medicine* 12: 3532–3542.
- Zhu, L., Wang, Yan, Yang, S., Li, Q., Wang, Jie, Zhao, J., dkk., 2025. Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang. *Journal of Patient-Reported Outcomes* 9: 107.